Secondary analysis of the IMmotion010 RCT (adjuvant atezolizumab vs placebo, high-risk localised RCC): in 80 matched primary and recurrent tumours, atezolizumab recurrences showed MHC-I downregulation; placebo recurrences more B cell and macrophage signatures.
Secondary analysisn = 80
Xu et al. Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma